$34.8m market cap

$0.22 last close

BioLargo has a number of subsidiaries and products focused on using iodine chemistry. CupriDyne is a product that is currently on the market for industrial odor control. The subsidiary Clyra Medical is a wound care company with an iodine-based irrigation solution and SkinDisc, a cell therapy for wounds. It is developing the AOS as a low-cost water purification device. Finally, the company has a full service environmental engineering team.

Investment summary

BioLargo is close to breaking even with both its Odor-No-More (ONM) and BioLargo Engineering Science & Technology (BLEST) divisions, which reported Q219 operating losses of $51,000 and $27,000, respectively (after $315,000 and $241,000 in revenue). Both businesses have been expanding with new contracts, which we expect to continue to improve margins. ONM recently signed its fourth national distribution agreement, and BLEST was awarded a series of environmental services contracts for US Air Force bases. The company continues to guide to ONM breaking even by YE19.

Share price graph
Price performance
Actual (11.6) 5.2 (15.0)
Relative* (14.8) 1.3 (17.6)
52-week high/low US$0.4/US$0.2
*% relative to local index
Key management
Dennis Calvert President & CEO